Jump Financial LLC Has $2.39 Million Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Jump Financial LLC lessened its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 87.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 98,949 shares of the company's stock after selling 712,848 shares during the quarter. Jump Financial LLC's holdings in Hims & Hers Health were worth $2,393,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. HighTower Advisors LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at $207,000. MML Investors Services LLC bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $197,000. Barclays PLC boosted its position in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company's stock worth $5,680,000 after acquiring an additional 27,231 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after acquiring an additional 482,177 shares during the last quarter. Finally, Sanctuary Advisors LLC lifted its position in Hims & Hers Health by 26.8% during the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock valued at $480,000 after purchasing an additional 5,505 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 100,000 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00. Following the sale, the chief executive officer now owns 27,918 shares of the company's stock, valued at $983,271.96. The trade was a 78.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 17,304 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $31.00, for a total transaction of $536,424.00. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at $6,001,631. This trade represents a 8.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 730,302 shares of company stock valued at $28,528,874 over the last three months. Insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Up 6.4 %

NYSE:HIMS traded up $1.71 on Thursday, reaching $28.42. The stock had a trading volume of 6,591,612 shares, compared to its average volume of 15,477,907. The company has a 50-day moving average of $35.50 and a 200 day moving average of $30.78. The stock has a market cap of $6.31 billion, a P/E ratio of 64.49 and a beta of 1.65. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HIMS shares. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Needham & Company LLC upped their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Finally, Bank of America upped their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $38.25.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.